The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We c...
Saved in:
| Main Authors: | Se Hwa Kim, Soo Young Yoon, Sung-Kil Lim, Yumie Rhee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/715908 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sclerostin levels in patients with acromegaly
by: Arnika Wydra, et al.
Published: (2025-08-01) -
Sclerostin
by: Stuart L. Silverman
Published: (2010-01-01) -
Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus
by: Cyril Traechslin, et al.
Published: (2025-06-01) -
Elevated sclerostin levels contribute to reduced bone mineral density in non-ambulatory stroke patients
by: Hye Kyoung Lee, et al.
Published: (2025-06-01) -
Sclerostin as a new target of diabetes-induced osteoporosis
by: Yanhua Li, et al.
Published: (2024-12-01)